Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Glucosylated nanomicelles target glucose-avid pediatric patient-derived sarcomas.
Bukchin A, Pascual-Pasto G, Cuadrado-Vilanova M, Castillo-Ecija H, Monterrubio C, Olaciregui NG, Vila-Ubach M, Ordeix L, Mora J, Carcaboso AM, Sosnik A. Bukchin A, et al. Among authors: olaciregui ng. J Control Release. 2018 Apr 28;276:59-71. doi: 10.1016/j.jconrel.2018.02.034. Epub 2018 Feb 28. J Control Release. 2018. PMID: 29501533
Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination.
Pascual-Pasto G, Olaciregui NG, Vila-Ubach M, Paco S, Monterrubio C, Rodriguez E, Winter U, Batalla-Vilacis M, Catala J, Salvador H, Parareda A, Schaiquevich P, Suñol M, Mora J, Lavarino C, de Torres C, Chantada GL, Carcaboso AM. Pascual-Pasto G, et al. Among authors: olaciregui ng. Cancer Lett. 2016 Sep 28;380(1):10-9. doi: 10.1016/j.canlet.2016.06.012. Epub 2016 Jun 16. Cancer Lett. 2016. PMID: 27319373
EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
Mohammad F, Weissmann S, Leblanc B, Pandey DP, Højfeldt JW, Comet I, Zheng C, Johansen JV, Rapin N, Porse BT, Tvardovskiy A, Jensen ON, Olaciregui NG, Lavarino C, Suñol M, de Torres C, Mora J, Carcaboso AM, Helin K. Mohammad F, et al. Among authors: olaciregui ng. Nat Med. 2017 Apr;23(4):483-492. doi: 10.1038/nm.4293. Epub 2017 Feb 27. Nat Med. 2017. PMID: 28263309
Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.
Monterrubio C, Paco S, Olaciregui NG, Pascual-Pasto G, Vila-Ubach M, Cuadrado-Vilanova M, Ferrandiz MM, Castillo-Ecija H, Glisoni R, Kuplennik N, Jungbluth A, de Torres C, Lavarino C, Cheung NKV, Mora J, Sosnik A, Carcaboso AM. Monterrubio C, et al. Among authors: olaciregui ng. J Control Release. 2017 Jun 10;255:108-119. doi: 10.1016/j.jconrel.2017.04.016. Epub 2017 Apr 12. J Control Release. 2017. PMID: 28412222 Free PMC article.
Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier.
Pascual-Pasto G, Olaciregui NG, Opezzo JAW, Castillo-Ecija H, Cuadrado-Vilanova M, Paco S, Rivero EM, Vila-Ubach M, Restrepo-Perdomo CA, Torrebadell M, Suñol M, Schaiquevich P, Mora J, Bramuglia GF, Chantada GL, Carcaboso AM. Pascual-Pasto G, et al. Among authors: olaciregui ng. J Control Release. 2017 Oct 28;264:34-44. doi: 10.1016/j.jconrel.2017.08.018. Epub 2017 Aug 19. J Control Release. 2017. PMID: 28830790
Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01.
Pascual-Pasto G, Bazan-Peregrino M, Olaciregui NG, Restrepo-Perdomo CA, Mato-Berciano A, Ottaviani D, Weber K, Correa G, Paco S, Vila-Ubach M, Cuadrado-Vilanova M, Castillo-Ecija H, Botteri G, Garcia-Gerique L, Moreno-Gilabert H, Gimenez-Alejandre M, Alonso-Lopez P, Farrera-Sal M, Torres-Manjon S, Ramos-Lozano D, Moreno R, Aerts I, Doz F, Cassoux N, Chapeaublanc E, Torrebadell M, Roldan M, König A, Suñol M, Claverol J, Lavarino C, Carmen de T, Fu L, Radvanyi F, Munier FL, Catalá-Mora J, Mora J, Alemany R, Cascalló M, Chantada GL, Carcaboso AM. Pascual-Pasto G, et al. Among authors: olaciregui ng. Sci Transl Med. 2019 Jan 23;11(476):eaat9321. doi: 10.1126/scitranslmed.aat9321. Sci Transl Med. 2019. PMID: 30674657 Clinical Trial.
ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma.
Carvalho D, Taylor KR, Olaciregui NG, Molinari V, Clarke M, Mackay A, Ruddle R, Henley A, Valenti M, Hayes A, Brandon AH, Eccles SA, Raynaud F, Boudhar A, Monje M, Popov S, Moore AS, Mora J, Cruz O, Vinci M, Brennan PE, Bullock AN, Carcaboso AM, Jones C. Carvalho D, et al. Among authors: olaciregui ng. Commun Biol. 2019 May 9;2:156. doi: 10.1038/s42003-019-0420-8. eCollection 2019. Commun Biol. 2019. PMID: 31098401 Free PMC article.
21 results